CSBio CSBio

X
[{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals conducts PK Study with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment of the Smallest Infants in the Connection Study Paused","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Strengthens the Clinical Development Organization in Preparation of the Start of the Phase III study CONCLUDE with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Next recruitment milestone reached in IBT\u2019s Phase III Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Gets New Patent for Cobitolimod Granted in Canada","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Enrols First Patient in The Phase III Study CONCLUDE With Cobitolimod in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Index Pharmaceuticals Gets New Patent for Cobitolimod Granted in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Index Pharmaceuticals Announces Successful Interactions With the PMDA for the Clinical Development of Cobitolimod in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Article Based on Infant Bacterial Therapeutics\u2019 (IBT) Connection Study published in the British Journal of Gastroenterology Demonstrates That One Day Shift In Sustained Feeding Tolerance (SFT) Correlates To Clinically Meaningful Outcomes.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Publishes Clinical Findings in The British Journal of Gastroenterology on The Convincing Association of Clinical Events to The Feeding Primary Endpoint of The \u2018Connection Study\u2019","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Updates the Timeline of The Phase Iii Study CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Provides Complementary Information on The Phase III Program CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Announces Positive Results from A Pharmacokinetic (PK) Study with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Opening of A Final Infant Cohort Will Accelerate Patient Recruitment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$50 million","upfrontCash":"$10 million","newsHeadline":"InDex Pharmaceuticals Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IBT Continues to Recruit Prematurely Born Infants to the Connection Study Following a Planned Safety Analysis.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Announces that all Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program CONCLUDE","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Kappaproct (cobitolimod) is a Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology Product Name: Kappaproct

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

            Lead Product(s): Lactobacillus Reuteri

            Therapeutic Area: Gastroenterology Product Name: IBP-9414

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.

            Lead Product(s): Lactobacillus Reuteri

            Therapeutic Area: Gastroenterology Product Name: IBP-9414

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Viatris will register and commercialize Kappaproct (cobitolimod), a TLR9 agonist being evaluated in phase III as a novel treatment for moderate to severe ulcerative colitis, in Japan.

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology Product Name: Kappaproct

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $50 million Upfront Cash: $10 million

            Deal Type: Licensing Agreement May 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in breast milk.

            Lead Product(s): Lactobacillus Reuteri

            Therapeutic Area: Gastroenterology Product Name: IBP-9414

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Kappaproct (cobitolimod) is a Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology Product Name: Kappaproct

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Kappaproct (cobitolimod) is a Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology Product Name: Kappaproct

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Patients responding to Kappaproct (cobitolimod) in the induction study will be eligible to continue in a one-year maintenance study, where they will be treated with either cobitolimod or placebo once every three weeks.

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology Product Name: Kappaproct

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acquired infections.

            Lead Product(s): Lactobacillus Reuteri

            Therapeutic Area: Gastroenterology Product Name: IBP-9414

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk,become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants.

            Lead Product(s): IBP-9414

            Therapeutic Area: Gastroenterology Product Name: IBP-9414

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY